

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

26 April 2018 (26.04.2018)



(10) International Publication Number

WO 2018/071959 A1

(51) International Patent Classification:

A61K 9/127 (2006.01) A61K 31/7068 (2006.01)

A61K 47/69 (2017.01) A61P 35/00 (2006.01)

A61K 39/395 (2006.01)

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/AU2017/050885

(22) International Filing Date:

18 August 2017 (18.08.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2016904292 21 October 2016 (21.10.2016) AU

(71) Applicant: BIOSCEPTRE (UK) LIMITED [GB/GB];

Jonas Webb Building, Babraham Cambridgeshire CB22
3AT (GB).

(72) Inventor; and

(71) Applicant (for AU only): BARDEN, Julian Alexander
[AU/AU]; c/- 11 Julius Avenue, North Ryde, New South
Wales 2113 (AU).

(72) Inventors: GONG, Xiaojuan; c/- 11 Julius Avenue, North
Ryde, New South Wales 2113 (AU). MOGHADDAM, Mi-
noo J; c/- 11 Julius Avenue, North Ryde, New South Wales
2113 (AU).

(74) Agent: FPA PATENT ATTORNEYS PTY LTD; Level
43, 101 Collins Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: CYTOTOXIC PARTICLES

(57) Abstract: The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 receptors on a cancer cell.

WO 2018/071959 A1

Cytotoxic particles

Cross-reference to related application

This application claims priority from Australian application AU 2016904292, the entire contents of which are herein incorporated by reference in their entirety.

Field of the invention

The invention relates to chemotherapy of cancer, to formation of nanoparticles, especially liposomes, and to conjugation of cytotoxic drugs and antibodies to same.

Background of the invention

Reference to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any jurisdiction or that this prior art could reasonably be expected to be understood, regarded as relevant, and/or combined with other pieces of prior art by a skilled person in the art.

Most cancers are frequently treated by a combination of approaches, including surgical removal of a tumour, chemotherapy, and/or radiation therapy. Surgical procedures are usually not sufficient to remove a tumour in its entirety, so surgery is frequently accompanied by chemotherapy and/or radiation therapy. Chemotherapy involves the use of drugs to kill tumour cells, and radiation therapy involves treatment with high-energy rays (e.g. x-rays) to kill or shrink tumour cells.

Unfortunately, chemotherapy and radiation cause serious and sometimes life-threatening side effects, including fatigue; nausea; vomiting; pain; hair loss; anemia; central nervous system problems; infection; blood clotting problems; mouth, gum, and throat problems; diarrhea; constipation; nerve and muscle effects; kidney and bladder effects; flu-like symptoms; fluid retention; and effects on sexual organs.

Chemotherapy causes such severe side effects because the treatment involves the systemic administration of cytotoxic agents to a patient. These agents cannot distinguish tumour cells from normal cells and, therefore, kill healthy cells as well as tumour cells. Side effects are worsened because a very large dose must be

administered to the patient in order to deliver a therapeutically effective dose to a tumour site. Although radiation therapy is administered somewhat more locally than chemotherapy, radiation treatment still results in the destruction of normal tissue in the vicinity of the tumour.

Thus, targeting of a therapeutic agent (e.g., to a particular tissue or cell type; to a specific diseased tissue but not to normal tissue; etc.) is desirable in the treatment of tissue specific diseases such as cancer (e.g. prostate cancer). For example, in contrast to systemic delivery of a cytotoxic anti-cancer agent, targeted delivery could prevent the agent from killing healthy cells. Additionally, targeted delivery would allow for the administration of a lower dose of the agent or at a lower administration frequency, which could reduce the undesirable side effects commonly associated with traditional chemotherapy.

In spite of advances in cancer therapy there remains a need for the targeted delivery of highly toxic agents to cancer cells.

15 **Summary of the invention**

The invention seeks to address the above mentioned need and in one embodiment provides a cytotoxic particle including:

- a core;
- a cytotoxic compound contained in, or entrapped in or on said core;
- a plurality of variable domains arranged on the core for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the cancer cell.

In another embodiment there is provided a cytotoxic particle including:

- a liposome;
- 25 - a cytotoxic compound contained in, or entrapped in or on said liposome;

- a plurality of variable domains arranged on the liposome for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the cancer cell.

In another embodiment there is provided a cytotoxic particle including:

- 5 - a liposome;
- a cytotoxic compound in the form of gemcitabine contained in, or entrapped in or on said liposome;
- a plurality of variable domains arranged on the liposome for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R
10 expressed thereon when the particle is contacted with the cancer cell.

In another embodiment there is provided a cytotoxic particle including:

- a liposome including hydrocarbon chains forming a lipid layer of the liposome;
- a cytotoxic compound in the form of gemcitabine, wherein the primary amine of gemcitabine is bonded to a hydrocarbon chain of the lipid layer via a carbamate group;
- 15 - a plurality of variable domains arranged on the liposome for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the cancer cell.

In another embodiment there is provided a cytotoxic particle including:

- a liposome including:
- 20 - hydrocarbon chains forming a lipid layer of the liposome
- maleimide groups arranged on the liposome enabling conjugation of an antibody thereto;
- a cytotoxic compound in the form of gemcitabine, wherein the primary amine of gemcitabine is bonded to a hydrocarbon chain of the lipid layer via a carbamate group;

- a plurality of variable domains bound to the maleimide groups arranged on the liposome for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the cancer cell.

5 In another embodiment there is provided a cytotoxic particle including:

- a liposome including:

- hydrocarbon chains forming a lipid layer of the liposome

- maleimide groups arranged on the liposome enabling conjugation of an antibody thereto;

10 - a cytotoxic compound in the form of gemcitabine, wherein the primary amine of gemcitabine is bonded to a hydrocarbon chain of the lipid layer via a carbamate group;

- a plurality of variable domains bound to the maleimide groups arranged on the liposome for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the

15 cancer cell,

wherein the variable domain is defined by Formula 1:

CDR1-CDR2-CDR3

wherein CDR1 is RNHDMG (SEQ ID NO: 4)

wherein CDR2 is AISGSGGSTYYANSVKG (SEQ ID NO: 5)

20 wherein CDR3 is EPKPMDETFDY (SEQ ID NO: 6).

Preferably, the variable domain contains framework regions in the formula FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

In another embodiment there is provided a cytotoxic particle including:

- a liposome including:

- hydrocarbon chains forming a lipid layer of the liposome

- maleimide groups arranged on the liposome enabling conjugation of an antibody thereto;

5 - a cytotoxic compound in the form of gemcitabine, wherein the primary amine of gemcitabine is bonded to a hydrocarbon chain of the lipid layer via a carbamate group;

- a plurality of variable domains bound to the maleimide groups arranged on the liposome for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the cancer cell,

10 wherein the variable domain has the following amino acid sequence (SEQ ID NO: 7):

EVQLLES G GGLVQP G GSLRLSCAAS G F TFRNHDMG WWRQAPG KGLEWWSAIS
GSGGSTYYANSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAEPKPM DTEFDYR
SPGTLVTVSS

15 In any embodiment, the primary amine of the gemcitabine is covalently bonded to a hydrocarbon chain of the lipid layer. Preferably the primary amine is the cytosine C4 amine of gemcitabine.

In any embodiment of the invention, the liposome is a spherical liposome.

20 In another embodiment, there is provided a pharmaceutical composition including a plurality of cytotoxic particles mentioned above and a pharmaceutically effective diluent, excipient or carrier. Typically, the pharmaceutical composition is adapted for intravenous administration.

25 In a further embodiment there is provided a method of treating an individual having cancer including administering a particle or composition mentioned above to the individual, thereby treating the individual for cancer.

In a further embodiment there is provided a method of reducing tumour volume in an individual having cancer comprising administering a particle or composition mentioned above to the individual, thereby reducing tumour volume in the individual.

In a further embodiment there is provided a particle or composition mentioned above for use in the treatment of an individual having cancer.

In a further embodiment, there is provided the use of a particle or composition mentioned above, in the manufacture of a medicament for the treatment of cancer.

5 In a further embodiment there is provided a method for killing a cancer cell including contacting a cancer cell with a particle or composition mentioned above.

In a further embodiment there is provided a kit including a particle or composition mentioned above.

10 In any aspect of the present invention, the cytotoxic compound may comprise gemcitabine. Preferably, the gemcitabine is in the form of a conjugate that allows the gemcitabine to be attached to or incorporated in the core or liposome.

In any aspect of the present invention, the core or liposome of the cytotoxic particle is comprised of dioleoylphosphatidylcholine (DOPC).

15 In any aspect of the present invention, the variable domain may be a single domain antibody or may be part of any other antibody structure as described herein. Further, the variable domain may be humanized or human.

In any aspect of the present invention, the plurality of variable domains are arranged on the core for selective binding to P2X₇R on a cancer cell. Further, the selective binding may be for a P2X₇R that is unable to form an apoptotic pore.

20 Further aspects of the present invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, given by way of example and with reference to the accompanying drawings.

Brief description of the drawings

25 **Figure 1** Cytotoxic nanoparticle formation showing the oleyl-gemcitabine conjugate and formation into a liposome.

Figure 2 Conjugation of antibody variable domains to liposome via maleimide groups.

Figure 3 Size distribution of liposomes.

Figure 4 Serological binding of liposomes by ELISA. Protein concentration after tangential flow filtration (TFF) washing is in the range of 400 to 500 µg/mL.

Figure 5 Conjugation of antibody to liposome demonstrated by SDS PAGE gel. Nupage 4-12% Bis tris gel, MOPS buffer (1X). The gel was run at 180V for 55mins.

Figure 6 Selective localisation of cytotoxic particles to 4T1 tumours.

Figure 7 Whole animal NIR imaging, revealing that (B) antibody-conjugated cytotoxic particles are retained in the tumour much longer than (A) non antibody-conjugated particles.

Figure 8 Nanoparticles are localised selectively: Mean total radiant efficiency $\pm$ SEM (p/s)/[AµW/cmA²] for excised tumour at 96 hr time point. Vehicle control (PBS; Group 1), uncoated nanoparticles (Group 2); Ab-coated nanoparticles (Group 3) and HEL4-coated nanoparticles (Group 4) were administered in a 50 µL volume once on Study Day 0 via intravenous tail vein injection

Figure 9 NIR signal strength at 96hr. *Ex vivo* bioluminescence imaging showed antibody coated NPs had higher accumulation in the excised tumour than naked nanoparticles. A: PBS group; B: uncoated nanoparticles; C: antibody coated nanoparticles; D: HEL4-coated nanoparticles.

Figure 10 Efficacy of antibody-conjugated nanoparticles on 4T1 murine breast tumour bearing mice: The mean tumour volume for each treatment group against days post inoculation. Treatment was given intravenously three times per week.

Figure 11 The effect of dosing frequency of antibody-coated nanoparticles: The mean tumour volume for each treatment group against days post inoculation. Treatment was given intravenously twice per week.

Detailed description of the embodiments

Reference will now be made in detail to certain embodiments of the invention. While the invention will be described in conjunction with the embodiments, it will be

understood that the intention is not to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims.

5 One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described.

10 It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

 All of the patents and publications referred to herein are incorporated by reference in their entirety.

15 The present invention provides for cytotoxic particles, comprised of a cytotoxic agent and having a plurality of variable domains arranged on the particles, wherein the variable domains allow for binding to P2X₇R on a cancer cell. The particles are able to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the cancer cell.

20 In certain aspects, the cytotoxic particles of the invention provide for sustained release of the cytotoxic agent, but also provide for reduced toxicity arising from the cytotoxic agent. This is because the variable domains for binding to P2X₇R ensure specificity for binding of the particles to cancerous tissue, and thereby reduce toxicity to healthy, non-cancerous tissue. The present invention therefore provides an advantage
25 over other means of providing cytotoxic agents to cancerous cells.

A. Definitions

For purposes of interpreting this specification, the following definitions will generally apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.

"Purinergic receptor" generally refers to a receptor that uses a purine (such as ATP) as a ligand.

"P2X₇ receptor" generally refers to a purinergic receptor formed from three protein subunits or monomers, with at least one of the monomers having an amino acid sequence substantially as shown in SEQ ID NO: 1 below:

SEQ ID NO:1

```

1      MPACCSCSDV FQYETNKVTR IQSMNYGTIK WFFHVLIIFS YCFALVSDKL YQRKEPVISS
61     VHTKVKGIAE VKKEIVENG V KKL VHSVFD T ADYTFPLQGN SFFVMTNFLK TEGQEQR LCP
121    EYPTRRTLCS SDRGCKKGWM DPQSKGIQTG RCVVHEGNQK TCEVSAWCPI EAVEEAPRPA
10 181    LLNSAENFTV LIKNNIDFPG HNYTTRN ILP GLNITCTFHK TQNPQCPIFR LGDIFRETGD
241    NFSDVAIQGG IMGIEIYWDC NLDRWFH HCR PKYSFRRLDD KTTNVS LYPG YNFRYAKYYK
301    ENNVEKRTLI KVF GIRFDIL VFGTGGKFDI IQLVVYIGST LSYFGLAAVF IDFLIDTYSS
361    NCCRSHIYPW CKCCQPCVVN EYYYRKKCES IVEPKPTLKY VSFVDESHIR MVNQQLLGRS
421    LQDVKGQEV P RPAMDFTDLS RLPLALH DTP PIPGQPEEIQ LLRKEATPRS RDSPVWCQCG
15 481    SCLPSQLPES HRCLEELCCR KKPGACITTS ELFRKLVL SR HVLQFLLLYQ EPLLALDVDS
541    TNSRLRH CAY R CYATWRFGS QDMADFA ILP SCCRW RIRKE FPKSEGQYSG FKSPY

```

To the extent that P2X₇ receptor is formed from three monomers, it is a "trimer" or "trimeric". "P2X₇ receptor" encompasses naturally occurring variants of P2X₇ receptor, e.g., wherein the P2X₇ monomers are splice variants, allelic variants and isoforms including naturally-occurring truncated or secreted forms of the monomers forming the P2X₇ receptor (e.g., a form consisting of the extracellular domain sequence or truncated form of it), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally- occurring allelic variants. In certain embodiments of the invention, the native sequence P2X₇ monomeric polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequence shown in SEQ ID NO: 1. In certain embodiments the P2X₇ receptor may have an amino

acid sequence that is modified, for example various of the amino acids in the sequence shown in SEQ ID NO: 1 may be substituted, deleted, or a residue may be inserted.

"Functional P2X₇ receptor" generally refers to a form of the P2X₇ receptor having three intact binding sites or clefts for binding to ATP. When bound to ATP, the functional
5 receptor forms a non-selective sodium/calcium channel that converts to a pore-like structure that enables the ingress of calcium ions and molecules of up to 900 Da into the cytosol, one consequence of which may be induction of programmed cell death. In normal homeostasis, expression of functional P2X₇ receptors is generally limited to cells that undergo programmed cell death such as thymocytes, dendritic cells, lymphocytes,
10 macrophages and monocytes. There may also be some expression of functional P2X₇ receptors on erythrocytes and other cell types.

"Non-functional P2X₇ receptor" generally refers to a form of a P2X₇ receptor having a conformation, distinct from functional P2X₇, whereby the receptor is unable to form an apoptotic pore, but which is still able to operate as a non-selective channel
15 through the maintenance of a single functional ATP binding site located between adjacent monomers. One example arises where one or more of the monomers has a cis isomerisation at Pro210 (according to SEQ ID NO: 1). The isomerisation may arise from any molecular event that leads to misfolding of the monomer, including for example, mutation of monomer primary sequence or abnormal post translational processing. One
20 consequence of the isomerisation is that the receptor is unable to bind to ATP at one or two ATP binding sites on the trimer and as a consequence not be able to extend the opening of the channel. In the circumstances, the receptor cannot form a pore and this limits the extent to which calcium ions may enter the cytosol. Non-functional P2X₇ receptors are expressed on a wide range of epithelial and haematopoietic cancers.

25 "Cancer associated -P2X₇ receptors" are generally P2X₇ receptors that are found on cancer cells (including, pre-neoplastic, neoplastic, malignant, benign or metastatic cells), but not on non-cancer or normal cells.

"E200 epitope" generally refers to an epitope having the sequence GHNYTTNILPGLNITC (**SEQ ID NO: 2**).

"E300 epitope" generally refers to an epitope having the sequence KYYKENNVEKRTLK (**SEQ ID NO: 3**).

"Composite epitope" generally refers to an epitope that is formed from the juxtaposition of the E200 and E300 epitopes or parts of these epitopes.

5 "Antibodies" or "immunoglobulins" or "Igs" are gamma globulin proteins that are found in blood, or other bodily fluids of vertebrates that function in the immune system to bind antigen, hence identifying and/or neutralizing foreign objects.

Antibodies are generally a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. Each L chain is linked to a H chain by one covalent disulfide bond. The two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bridges.

H and L chains define specific Ig domains. More particularly, each H chain has at the N-terminus, a variable domain (VH) followed by three constant domains (CH) for each of the α and γ chains and four CH domains for μ and ϵ isotypes. Each L chain has at the N-terminus, a variable domain (VL) followed by a constant domain (CL) at its other end. The VL is aligned with the VH and the CL is aligned with the first constant domain of the heavy chain (CHL).

Antibodies can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated α , δ , ϵ , γ , and μ , respectively. The γ and α classes are further divided into subclasses on the basis of relatively minor differences in $\frac{3}{4}$ sequence and function, e.g., humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.

The constant domain includes the Fc portion which comprises the carboxy-terminal portions of both H chains held together by disulfides. The effector functions of antibodies such as ADCC are determined by sequences in the Fc region, which region is also the part recognized by Fc receptors (FcR) found on certain types of cells.

The pairing of a VH and VL together forms a "variable region" or "variable domain" including the amino -terminal domains of the heavy or light chain of the antibody. The variable domain of the heavy chain may be referred to as "VH." The variable domain of the light chain may be referred to as "VL." The V domain contains an
5 "antigen binding site" which affects antigen binding and defines specificity of a particular antibody for its particular antigen. V regions span about 110 amino acid residues and consist of relatively invariant stretches called framework regions (FRs) (generally about 4) of 15-30 amino acids separated by shorter regions of extreme variability called
10 "hypervariable regions" (generally about 3) that are each generally 9-12 amino acids long. The FRs largely adopt a β -sheet configuration and the hypervariable regions form loops connecting, and in some cases forming part of, the β -sheet structure.

"Hypervariable region" refers to the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops. Generally, antibodies comprise six hypervariable regions; three in the VH (H1, H2, H3), and three
15 in the VL (L1, L2, L3).

"Framework" or "FR" residues are those variable domain residues other than the hypervariable region residues herein defined.

An "antigen binding site" generally refers to a molecule that includes at least the hypervariable and framework regions that are required for imparting antigen binding
20 function to a V domain. An antigen binding site may be in the form of an antibody or an antibody fragment, (such as a dAb, Fab, Fd, Fv, F(ab')₂ or scFv) in a method described herein.

An "intact" or "whole" antibody is one which comprises an antigen-binding site as well as a CL and at least heavy chain constant domains, CH1, CH2 and CH3. The
25 constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof.

"Whole antibody fragments including a variable domain" include Fab, Fab', F(ab')₂, and Fv fragments; diabodies; linear antibodies, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

The "Fab fragment" consists of an entire L chain along with the variable region domain of the H chain (VH), and the first constant domain of one heavy chain (CH1). Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site.

5 A "Fab' fragment" differs from Fab fragments by having additional few residues at the carboxy terminus of the CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.

10 A "F(ab')₂ fragment" roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen.

An "Fv" is the minimum antibody fragment which contains a complete antigen-recognition and binding site. This fragment consists of a dimer of one heavy and one light chain variable region domain in tight, non-covalent association.

15 In a single-chain Fv (scFv) species, one heavy and one light chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure analogous to that in a two-chain Fv species. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody.

20 "Single-chain Fv" also abbreviated as "sFv" or "scFv" are antibody fragments that comprise the VH and VL antibody domains connected to form a single polypeptide chain. Preferably, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding.

25 A "single variable domain" is half of an Fv (comprising only three CDRs specific for an antigen) that has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

"Diabodies" refers to antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain

variable domain (VL) in the same polypeptide chain (VH-VL). The small antibody fragments are prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10 residues) between the VH and VL domains such that interchain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent
5 fragment, i.e., fragment having two antigen-binding sites.

Diabodies may be bivalent or bispecific. Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the VH and VL domains of the two antibodies are present on different polypeptide chains. Triabodies and tetrabodies are also generally known in the art.

10 An "isolated antibody" is one that has been identified and separated and/or recovered from a component of its pre-existing environment. Contaminant components are materials that would interfere with therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.

15 A "human antibody" refers to an antibody that possesses an amino acid sequence that corresponds to that of an antibody produced by a human. Human antibodies can be produced using various techniques known in the art, including phage-display libraries. Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled.

20 "Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse,
25 rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine
30 antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the

hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

5 "Monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site or determinant on the antigen. In addition to their
10 specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. Monoclonal antibodies may be prepared by the hybridoma methodology. The "monoclonal antibodies" may also be isolated from phage antibody libraries using molecular engineering techniques.

The term "anti-P2X₇ receptor antibody" or "an antibody that binds to P2X₇
15 receptor" refers to an antibody that is capable of binding P2X₇ receptor with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting P2X₇ receptor, typically non-functional P2X₇ receptor or a cancer associated P2X₇ receptor. Preferably, the extent of binding of an P2X₇ receptor antibody to an unrelated protein is less than about 10% of the binding of the antibody to P2X₇ receptor
20 as measured, e.g., by a radioimmunoassay (RIA), Enzyme-Linked Immunosorbent Assay (ELISA), Biacore or Flow Cytometry. In certain embodiments, an antibody that binds to P2X₇ receptor has a dissociation constant (K_d) of < 1 μM, < 100 nM, < 10 nM, < 1 nM, or < 0.1 nM. An anti non-functional P2X₇ receptor antibody is generally one having some or all of these serological characteristics and that binds to non-functional
25 P2X₇ receptors but not to functional P2X₇ receptors.

An "affinity matured" antibody is one with one or more alterations in one or more hypervariable region thereof that result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody that does not possess those alteration(s). Preferred affinity matured antibodies will have nanomolar or even picomolar affinities for
30 the target antigen. Affinity matured antibodies are produced by procedures known in the art.

A "blocking" antibody" or an "antagonist" antibody is one that inhibits or reduces biological activity of the antigen it binds. Preferred blocking antibodies or antagonist antibodies substantially or completely inhibit the biological activity of the antigen.

5 An "agonist antibody", as used herein, is an antibody, which mimics at least one of the functional activities of a polypeptide of interest.

"Binding affinity" generally refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1 : 1 interaction between
10 members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies generally bind antigen slowly and tend to dissociate readily, whereas high-affinity antibodies generally bind antigen faster and tend to remain bound
15 longer. A variety of methods of measuring binding affinity are known in the art, any of which can be used for purposes of the present invention.

"Epitope" generally refers to that part of an antigen that is bound by the antigen binding site of an antibody. An epitope may be "linear" in the sense that the hypervariable loops of the antibody CDRs that form the antigen binding site bind to a
20 sequence of amino acids as in a primary protein structure. In certain embodiments, the epitope is a "conformational epitope" i.e. one in which the hypervariable loops of the CDRs bind to residues as they are presented in the tertiary or quaternary protein structure.

'Treatment' generally refers to both therapeutic treatment and prophylactic or
25 preventative measures.

Subjects requiring treatment include those already having a benign, pre-cancerous, or non-metastatic tumour as well as those in which the occurrence or recurrence of cancer is to be prevented.

The objective or outcome of treatment may be to reduce the number of cancer
30 cells; reduce the primary tumour size; inhibit (i.e., slow to some extent and preferably

stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumour metastasis; inhibit, to some extent, tumour growth; and/or relieve to some extent one or more of the symptoms associated with the disorder.

5 Efficacy of treatment can be measured by assessing the duration of survival, time to disease progression, the response rates (RR), duration of response, and/or quality of life.

"Pre-cancerous" or "pre-neoplasia" generally refers to a condition or a growth that typically precedes or develops into a cancer. A "pre-cancerous" growth may have cells that are characterized by abnormal cell cycle regulation, proliferation, or
10 differentiation, which can be determined by markers of cell cycle.

Other examples of cancer include blastoma (including medulloblastoma and retinoblastoma), sarcoma (including liposarcoma and synovial cell sarcoma), neuroendocrine tumours (including carcinoid tumours, gastrinoma, and islet cell cancer), mesothelioma, schwannoma (including acoustic neuroma), meningioma,
15 adenocarcinoma, melanoma, leukemia or lymphoid malignancies, lung cancer including small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma,
20 breast cancer (including metastatic breast cancer), colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, tumours of the biliary tract, as well as head and neck cancer.

25 "A condition or symptom associated" [with the cancer] may be any pathology that arises as a consequence of, preceding, or proceeding from the cancer. For example, where the cancer is a skin cancer, the condition or relevant symptom may be microbial infection. Where the cancer is a secondary tumour, the condition or symptom may relate to organ dysfunction of the relevant organ having tumour metastases. In one
30 embodiment, the methods of treatment described herein are for the minimisation or

treatment of a condition or symptom in an individual that is associated with a cancer in the individual.

As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and
5 "comprised", are not intended to exclude further additives, components, integers or steps. The terms "including" and "comprising" may be used interchangeably.

B. Cytotoxic particles

In one embodiment there is provided a cytotoxic particle including:

- a core
- 10 - a cytotoxic compound contained in, or entrapped in or on said core;
- a plurality of variable domains arranged on the core for binding to P2X₇ receptors on a cancer cell, the arrangement enabling the particle to cross link P2X₇ receptors on a cancer cell when the particle is contacted with a cancer cell.

B.1 Core

15 The core may generally define the overall dimensions and physical characteristics of the particle.

The core may be formed from lipid, protein, sugar or other biomolecule. Alternatively, the core may be formed of a polymer, resin, plastic or ceramic or glass.

In one particularly preferred embodiment the core is provided in the form of a
20 liposome, micelle, microemulsion or macroemulsion.

Micelles are colloidal aggregates of amphipathic (surfactant) molecules that are formed at a well-defined concentration known as the critical micelle concentration. Micelles are oriented with the nonpolar portions at the interior and the polar portions at the exterior surface, exposed to water. The typical number of aggregated molecules in a
25 micelle (aggregation number) is 50 to 100.

Microemulsions are essentially swollen micelles, although not all micellar solution can be swollen to form microemulsion. Microemulsions are thermodynamically stable, are formed spontaneously, and contain particles that are extremely small. Droplet diameters in microemulsions typically range from 10-100 nm.

5 Macroemulsions are droplets with diameters greater than 100 nm.

Liposomes are closed lipid vesicles comprising lipid bilayers that encircle aqueous interiors. Liposomes typically have diameters of 25 nm to 1 μ m (see, e.g., D.O. Shah (ed), 1998, *Micelles, Microemulsions, and Monolayers: Science and Technology*, Marcel Dekker; A.S. Janoff (ed), 1998, *Liposomes: Rational Design*, Marcel Dekker).

10 Preferably the core is provided in the form of a liposome. In this embodiment, the particle may be described as an antibody-liposome conjugate.

The liposome may consist of lipids including phosphoglycerides and sphingolipids, representative examples of which include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid,
15 palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoyl - phosphatidylcholine or dilinoleoylphosphatidylcholine. Other compounds lacking in phosphorus, such as sphingolipid and glycosphingolipid families are also contemplated. Additionally, the amphipathic lipids described above may be mixed with other lipids
20 including triacylglycerols and sterols.

The liposome may have a diameter ranging between about 50nm and 200 μ m. Accordingly, the liposome may be a small, sonicated unilamellar vesicle (SUV), a large unilamellar vesicle (LUV), or a liposome prepared by reverse phase evaporation (a REV), by French press (a FPV) or by ether injection (an EIV). Methods of preparing
25 liposomes of such sizes, including methods of fractionating and purifying liposomes of the desired size, are known to one skilled in the art. Typically, the liposome has a diameter ranging between about 10 and 600 nm. In one embodiment, the liposome has a diameter of between about 50 and 200 nm. In one embodiment, the liposome is a LUV.

Typically, the liposome of the invention is a unilamellar with respect to the liposome lipid bilayer. However, it will be understood that the liposome of the invention may comprise more than one lipid bilayer. Thus in one embodiment, the liposome may be a multilamellar vesicle such as a large, vortexed multilamellar vesicle (MLV).

5 As described herein a compound for providing the liposome with a charge for binding the liposome to a cancer cell is advantageous for improving the fusion between the cancer cell lipid bilayer and the liposome bilayer. For example, DOTAP is particularly useful as a binding means for binding the liposome lipid bilayer to a target cell.

10 The liposome may be adapted for destabilisation of the liposome lipid bilayer at the pH of an early endosome. An early endosome is a vacuole or vesicle formed at an early stage of the endocytotic pathway. This organelle typically has a pH ranging from 5.5 to 6.0.

15 Liposomes can be constructed by well-known techniques (see, e.g., G. Gregoriadis (ed.), 1993, Liposome Technology Vols. 1-3, CRC Press, Boca Raton, FL). Lipids are typically dissolved in chloroform and spread in a thin film over the surface of a tube or flask by rotary evaporation. If liposomes comprised of a mixture of lipids are desired, the individual components are mixed in the original chloroform solution. After the organic solvent has been eliminated, a phase consisting of water optionally
20 containing buffer and/or electrolyte is added and the vessel agitated to suspend the lipid. This mixture can then be emulsified by the use of a homogenizer, lyophilized, and melted to obtain multilamellar liposomes. Alternatively, unilameilar liposomes can be produced by the reverse phase evaporation method (Szoka and Papahadjopoulos, 1978, Proc. Natl. Acad. Sci. USA 75:4194-4198). Unilameilar vesicles can also be
25 prepared by sonication or extrusion. Sonication is generally performed with a bath-type sonifier, such as a Branson tip sonifier (G. Heinemann Ultrashall und Labortechnik, Schwabisch Gmund, Germany) at a controlled temperature as determined by the melting point of the lipid. Extrusion may be carried out by biomembrane extruders, such as the Lipex Biomembrane Extruder (Northern Lipids Inc, Vancouver, British Columbia,
30 Canada). Defined pore size in the extrusion filters may generate unilameilar liposomal vesicles of specific sizes. The liposomes can also be formed by extrusion through an

asymmetric ceramic filter, such as a Ceraflow Microfilter (commercially available from the Norton Company, Worcester, MA).

Following liposome preparation, the liposomes that have not been sized during formation may be sized by extrusion to achieve a desired size range and relatively narrow distribution of liposome sizes. A size range of about 0.1-0.5 microns will allow the liposome suspension to be sterilized by filtration through a conventional filter (e.g., a 0.22 micron filter or other filter). The filter sterilization method can be carried out on a high throughput basis.

Several techniques are available for sizing liposomes to a desired size, including, ultrasonication, high-speed homogenization, and pressure filtration (M.J. Hope et al., 1985, *Biochimica et Biophysica Acta* 812:55; U.S. Patent Nos. 4,529,561 and 4,737,323). Sonicating a liposome suspension either by bath or probe sonication produces a progressive size reduction down to small unilameilar vesicles less than about 0.05 microns in size. Multilamellar vesicles can be recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 0.1 and 0.5 microns, and preferably between about 0.1 and 0.2 microns. The size of the liposomal vesicles may be determined by quasi-elastic light scattering (QELS) (see Bloomfield, 1981, *Ann. Rev. Biophys. Bioeng.* 10:421-450). Average liposome diameter may be reduced by sonication of formed liposomes. Intermittent sonication cycles may be alternated with QELS assessment to guide efficient liposome synthesis.

Liposomes can be extruded through a small-pore polycarbonate membrane or an asymmetric ceramic membrane to yield a well-defined size distribution. Typically, a suspension is cycled through the membrane one or more times until the desired liposome size distribution is achieved. The liposomes may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in liposome size.

In a particularly preferred embodiment, the cytotoxic particle includes a core in the form of a liposome, wherein the liposome includes oleic acid fatty acid chains in a lipid layer of the liposome. The core is preferably in the form of spherical bilayer membranes to form the liposome. The oleic acid may be functionalised to form a carbamate group for binding to gemcitabine, or functionalised with maleimido groups for

binding to an immunoglobulin domain. Preferably the liposomes have a size of about 60 to 150nm.

B.2 Variable domains

5 The variable domains arranged on the core for binding to P2X₇ receptors on a cancer cell may be provided in the form of a whole antibody, or a fragment of an antibody that includes a variable domain.

In one embodiment, the variable domains are for binding to cancer associated - P2X₇ receptors.

10 In another embodiment, the variable domains are for binding to non-functional P2X₇ receptors.

In one embodiment, the variable domain is one that discriminates between functional and non-functional P2X₇ receptors, so as to bind to non-functional receptors, but not to functional receptors. Examples of variable domains are those that bind to the E200 epitope, E300 epitope or composite epitope as for example in
15 PCT/AU2002/000061, PCT/AU2002/001204, PCT/AU2007/001540,
PCT/AU2007/001541, PCT/AU2008/001364, PCT/AU2008/001365,
PCT/AU2009/000869 and PCT/AU2010/001070, all of which are incorporated by reference.

20 Fragments of variable domains include single chain antibodies, single chain Fv fragments, and F(ab')₂, Fab, Fd and Fv fragments.

The variable domains may arise from monoclonal or polyclonal antiserum.

The variable domains may be human, humanised, chimeric, mouse, rat, rabbit or other mammalian species.

The variable domain may be affinity matured.

25 The antibodies in which the variable domains are arranged may have multiple specificities or valencies.

The variable domain may be adapted so as to be suited to administration by a selected method.

The variable domain may be provided in an antibody of any isotype. The antibody may be produced by hybridoma, or by recombinant expression, or may be
 5 obtained from serum for example as obtainable from a mammal, particularly a human or mouse. The antibody may also be obtained from an avian.

In a particularly preferred embodiment, the variable domain is defined by Formula
 1:

CDR1-CDR2-CDR3

10 wherein CDR1 is RNHDMG (**SEQ ID NO: 4**)

wherein CDR2 is AISGSGGSTYYANSVKG (**SEQ ID NO: 5**)

wherein CDR3 is EPKPMDFEFDY (**SEQ ID NO: 6**)

In a particularly preferred embodiment, the variable domain has the following amino acid sequence (**SEQ ID NO: 7**):

15 EVQLLES GGGLVQPGGSLRLSCAASGFTFRNHDMGWWRQAPGKGLEWWSAIS
 GSGGSTYYANSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAEPKPMDFEFDYR
 SPGTLVTVSS

or

20 EVQLLES GGGLVQPGGSLRLSCAASGFTFRNHDMGWWRQAPGKGLEWWSAIS
 GSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAEPKPMDFEFDYR
 SPGTLVTVSS (SEQ ID NO: 8).

B.3 Conjugation of variable domains to liposomes

The variable domains or antibodies can be conjugated to liposomes using conventional techniques (see, e.g., M.J. Ostro (ed.) 1987, Liposomes: from Biophysics
 25 to Therapeutics, Marcel Dekker, New York, NY). One preferred method of preparing liposomes and conjugating immunoglobulins to their surface is described by Y. Ishimoto et al., 1984, J. Immunol. Met. 75:351-360. In accordance with this method, multilamellar

liposomes composed of dipalmitoylphosphatidylcholine, cholesterol, and phosphatidylethanolamine are prepared. Purified fragments are then coupled to the phosphatidylethanolamine by the cross-linking agent N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate. The coupling of the antibody or fragment to the liposome is demonstrated by the release of a pre-trapped marker, e.g., carboxyfluorescence, from the liposomes. This release occurs upon incubation with a secondary antibody against the conjugated antibody, fragment, or complement.

The variable domains and antibodies can also be coupled to a liposome or another carrier of the invention via carbohydrate moieties. Such coupling can be used provided that the carbohydrate moiety is not in the hypervariable region or at the antibody binding sites. In this way, conjugation via the cross-linking with the carbohydrate will not affect binding, and the binding sites will still be available to bind to cell surface antigens. One preferred method for coupling antibodies or antibody fragments of the invention (other than Fv) to a polymer backbone or a liposome involves conjugation through the carbohydrate moieties in the constant regions. This maximizes the number of available antigen-binding sites. Methods for derivatizing sugar ring moieties to create hydrazide groups for coupling with antibody fragments (and antibodies) have been established (see J.D. Rodwell et al., 1986, Proc. Natl. Acad. Sci. USA 83:2632-36). Several immunoconjugates prepared in this way are in clinical studies or pending approval for routine clinical uses.

Binding of a monoclonal antibody to the surface of a liposome may also be accomplished by the formation of cross-linkage between phosphatidylethanolamine and the antibody using glutaraldehyde. Similarly, the targeting antibody may be cross-linked to the liposome via a reactive PEG group anchored on the surface of the liposome and acting as a stealth coating.

Alternatively, a thiolated antibody can be allowed to react with a liposome comprising a lipid into which a maleimide group has been incorporated. Remaining maleimide groups on the surface of the liposome may be further reacted with a compound containing thiolated polyalkyleneglycol moiety. Thiolation of an antibody or antibody fragment may be achieved through use of N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), which is usually used for thiolation of protein,

iminothiolane, or mercaptoalkylimidate. Alternatively, a dithiol group endogenous to an antibody may be reduced to form a thiol group. The latter method is preferred for maintaining antibody function. In accordance with another method, whole antibodies are treated with an enzyme such as pepsin to form F(ab)₂ fragments, which are then
 5 reduced with dithiothreitol (DTT) to form Fab fragments, which results in the production of one to three thiol groups. The conjugation of the thiolated antibody to the maleimide group-containing liposome may be accomplished by reacting the components in a neutral buffer solution at pH 6.5-7.5 for 2-16 hours.

B. 3 Cytotoxic drugs

10 Preferably the cytotoxic drug is a nucleoside analogue that, when incorporated into a nucleic acid strand during replication leads to apoptosis.

Preferably the nucleoside analogue is a pyrimidine.

The pyrimidine may be selected from gemcitabine (4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on) (Gemzar). or cytarabine (4-
 15 amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl]-1,2-dihydro pyrimidin -2-one or ara-C),

Preferably the pyrimidine is gemcitabine.

B. 4 Conjugation of cytotoxic drugs to liposome

Generally a cytotoxic drug may be conjugated to a liposome by functionalising a
 20 lipid component for forming a lipid layer of the liposome and then reacting the functional group with a cytotoxic agent so as to form a lipid-drug conjugate. The drug conjugate is then mixed with other lipid components and conditions applied for formation of a liposome as described above. In one embodiment an oleic acid hydrocarbon fatty acid chain is functionalised enabling the formation of a carbamate group between the
 25 cytotoxic agent and the oleic acid.

C. Pharmaceutical compositions & cancer therapy

In one embodiment there is provided a pharmaceutical composition including a plurality of cytotoxic particles according to the invention and a pharmaceutically effective

diluent, excipient or carrier. In one embodiment, the particle for use in the composition has a core in the form of a liposome.

The particles of the composition may have the same density of variable domains.

The core of each particle in the composition may have the same surface area

5 In one embodiment there is provided a method of treating an individual for a cancer, especially a cancer including cancer cells that have a low copy number or low expression or production of cell surface P2X₇R, including providing a therapeutically effective amount of a particle or composition mentioned above to the individual, thereby treating the individual for cancer. In this embodiment there is provided a particle or
10 composition mentioned above for use in the treatment of an individual having cancer, wherein the cancer includes cancer cells that have a low copy number or low expression or production of cell surface P2X₇R.

The particles or compositions of the invention may be administered to a subject in need thereof by oral, parenteral (e.g. intravenous, intra-arterial, intraperitoneal,
15 intramuscular, subcutaneous, intradermal, rectal or vaginal) route, by inhalation or topical application. One form for administration would be a solution for injection, in particular for intravenous or intra-arterial injection or drip, comprising a buffer (e.g. acetate, phosphate or citrate buffer), a surfactant (e.g. polysorbate), optionally a stabilizer agent (e.g. human albumin). In other methods particles can be delivered
20 directly to the site of disease thereby increasing the exposure of the diseased cell or tissue to the antibody.

Preparations for parenteral administration includes sterile aqueous (aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media) or non-aqueous (non-aqueous solvents are propylene
25 glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate) solutions, suspensions, and emulsions. Pharmaceutically acceptable carriers include between 0.01 to 0.1 M and preferably 0.05 M phosphate buffer or 0.9% saline. Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed
30 oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte

replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

More particularly, pharmaceutical compositions suitable for injectable use include
5 sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions, in such cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and will preferably be preserved against the contaminating action of microorganisms,
10 such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of
15 surfactants. Suitable formulations for use in the therapeutic methods disclosed herein are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., 16th ed. (1980).

Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol,
20 ascorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatine.

25 In any case, sterile injectable solutions can be prepared by incorporating a particle of the invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other
30 ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are

vacuum drying, freeze-drying and spray drying, which yields a powder of an active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The preparations for injections are processed, filled into containers such as ampoules, bags, bottles, syringes or vials, and sealed under aseptic conditions according to methods known in the art. Further, the preparations may be packaged and sold in the form of a kit. Such articles of manufacture will preferably have labels or package inserts indicating that the associated compositions are useful for treating a subject suffering from, or predisposed to disorders.

Effective doses of the compositions of the present invention, for treatment of disorders, as described herein, vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Treatment dosages may be titrated using routine methods known to those of skill in the art to optimize safety and efficacy.

The particles of the invention can be administered before, during or after surgical intervention for resection or removal of tumour or tissue.

In one embodiment, the method is particularly useful for delaying disease progression.

In one embodiment, the method is particularly useful for extending survival of the human, including overall survival as well as progression free survival.

In one embodiment, the method is particularly useful for providing a complete response to therapy whereby all signs of cancer in response to treatment have disappeared. This does not always mean the cancer has been cured.

In one embodiment, the method is particularly useful for providing a partial response to therapy whereby there has been a decrease in the size of one or more tumours or lesions, or in the extent of cancer in the body, in response to treatment.

In one embodiment, the cancer is pre-cancerous or pre-neoplastic.

In one embodiment, the cancer is a secondary cancer or metastases. The secondary cancer may be located in any organ or tissue, and particularly those organs

or tissues having relatively higher hemodynamic pressures, such as lung, liver, kidney, pancreas, bowel and brain.

D. Assays for activity

The activities of the particles of the invention may be measured *in vitro* with reference to various cell function parameters including cytotoxicity, cytostasis, apoptosis induction, cell morphology, cytokine production, signal transduction, cell proliferation and activation status and protein expression and activation. Other biologically appropriate endpoints may also be considered.

In some particular embodiments of the invention activity may be assessed by means of a MTT assay or XTT assay (cell proliferation); a trypan blue exclusion assay (cell viability); membrane phosphoserine asymmetry, annexin 5 binding and caspase assays (apoptosis); and cytokine production (cell function).

The assay may employ a cell line expressing P2X₇R. Preferably cell lines having high copy number, or production or expression of P2X₇R (such as PC3, discussed below) and cells having low copy number or production or expression of P2X₇R (such as COLO25, discussed below) are utilised.

In one embodiment, these assays may be particularly useful for determining the amount of variable domain to arrange on the core of the particle.

Examples

Example 1: Liposome formation

The manufacture of immunoliposomes consists of two main parts: nanoparticle construction and antibody conjugation.

Nanoparticle construction: Nanoparticles recipients are DOPC (from Avanti Polar Lipids), Gem-Ole (synthesised by reaction oleyl chlorofomate to the hydroxyl-protected Gemcitabine base via carbamate chemical linkage, SOP-Syn001-002) and Maleimido-Succinyl-PEG4000-Oleate (synthesised by converting Succinyl PEG4000-Oleate to Maleimido-Succinyl-PEG4000-Oleate, SOP-Syn 003-005). 43% DOPC, 30% Gem Ole

and 27% Maleimido-Succinyl-PEG4000-Oleate are dissolved in EtOH and a thin film is generated through rotary evaporation. The thin film is further hydrated with 1x PBS to the concentration of 10 mg/mL. The hydrated nanoparticle solution is sonicated for 2 min then passed through a 200 nm membrane three times and a 100 nm membrane six
5 times to yield a translucent nanoparticle solution with the average size of 50-100 nm mean diameter.

Antibody conjugation: The antibody is activated via Traut's reagent prior to mixing with nanoparticle solution. The conjugated nanoparticles are quenched with L-cysteine and purified via tangential flow filtration. The immunoliposomes are then further
10 extruded through a 100 nm membrane three times and followed by sterile filtration through a 200 nm membrane. The antibody used herein was a single domain antibody. The single domain antibody comprised the CDR sequences as shown in SEQ ID NOs: 4, 5 and 6. Further, the variable domain comprised the amino acid sequence as shown in SEQ ID NO: 7.

15 Figure 1 is a schematic of the cytotoxic nanoparticle formation showing the oleyl-gemcitabine conjugate and formation into a liposome. Figure 2 shows conjugation of antibody variable domains to liposomes via maleimide groups. Figure 3 shows the size distribution of the liposomes.

Example 2: Binding specificity of cytotoxic nanoparticles

20 Conjugation of antibody to liposome was demonstrated by SDS PAGE gel Nupage 4-12% Bis tris gel, MOPS buffer (1X) (see Figure 5).

The liposomes of the invention were also assessed for their ability to bind to the E200 epitope of P2X₇R. The results (by ELISA, and shown in Figure 4), demonstrate that the nanoparticles have particle affinity for the E200 epitope. Accordingly, the
25 liposomes of the invention provide for selective binding to cancerous cells expressing non-functional P2X₇R.

Example 3: Biodistribution imaging of fluorescently labelled nanoparticles in 4T1-luc2 tumour bearing mice

The near-infrared (NIR) lipophilic fluorescent dye DiR (ThermoFisher) was incorporated into the lipid bilayer of naked nanoparticles, nanoparticles coated with HEL4 (isotype) and nanoparticles coated with variable domains for binding to anti-P2X₇R (P2X₇-binding domain-coated nanoparticles, or “BIL03s-coated”). Female Balb/c mice were inoculated orthotopically (4th mammary fat pad) with 4T1-luc2 murine breast cancer cells. A 50 µL dose of nanoparticles was injected intravenously at study day 0 and near-infrared (NIR) imaging was performed at 6, 12, 24, 48 and 96 post treatment. At termination, excised liver, spleen and tumour NIR imaging was performed and bioluminescence imaging was performed on tumour tissues.

Whole animal NIR imaging and *ex vivo* bioluminescence showed that there was greater accumulation in tumours of nanoparticles coated with P2X₇R-binding domains (BIL03s) than control nanoparticles (either naked particles or HEL4-coated) (see Figures 6 and 7). In particular, figure 6 shows selective localisation of cytotoxic particles to 4T1 tumours. Antibody-conjugated cytotoxic particle accumulation in the tumour is much greater than for non-antibody-conjugated particles (Figures 7 and 9). Specifically, Figure 9 shows by *ex vivo* bioluminescence imaging that antibody coated nanoparticles had higher accumulation in the excised tumour than naked nanoparticles.

Figure 8 shows that the nanoparticles are localised selectively: Mean total radiant efficiency $\pm$ SEM (p/s)/[AµW/cmA²] for excised tumour at 96 hr time point. Vehicle control (PBS; Group 1), uncoated nanoparticles (Group 2); Ab-coated nanoparticles (Group 3) and HEL4-coated nanoparticles (Group 4) were administered in a 50 µL volume once on Study Day 0 via intravenous tail vein injection.

Example 4: Efficacy of gemcitabine liposome nanoparticles conjugated to a domain for binding to P2X₇R

This study aimed to determine the efficacy of P2X₇-binding domain-coated nanoparticles (i.e., “BIL03s-coated”) and HEL4-coated nanoparticles to deliver the cytotoxic agent gemcitabine to tumours in the 4T1 murine breast tumour model.

Nanoparticles were administered intravenously, 3 times a week. Nanoparticles contained either 0.2 mg gemcitabine or PBS buffer (control).

Tumour volume was measured over the study period (see Figure 10). Mice were terminated when estimated tumour volume exceeded 1000 mm³.

5 Figure 10 shows efficacy of antibody-conjugated nanoparticles on 4T1 murine breast tumour bearing mice. Figure 11 shows the effect of dosing frequency of antibody-coated nanoparticles.

10 The results showed that the P2X₇-binding domain-coated nanoparticles containing gemcitabine provided greater tumour suppression and prolonged survival compared with HEL4-coated nanoparticles containing gemcitabine (P=0.0456).

Example 5: Dosing regimen investigation

15 Figure 11 shows the results of a study comparing the efficacy of P2X₇-binding domain-coated nanoparticles containing gemcitabine to gemcitabine alone for inhibiting tumour growth. The study compared the results following administration of 0.3 mg gemcitabine ("free gemcitabine") or P2X₇-binding domain-coated nanoparticles containing gemcitabine, equivalent to a dose of 0.3 mg gemcitabine.

The efficacy of both treatments was comparable, indicating that one benefit of the P2X₇-binding domain-coated nanoparticles is the ability to reduce the frequency of dosing if using P2X₇-binding domain-coated nanoparticles.

20 The coated nanoparticles provide for sustained release and lower toxicity, thereby providing an advantage over existing cancer treatments.

25 The findings of *in vivo* studies also indicate that greater efficacy of P2X₇-binding domain-coated nanoparticles containing gemcitabine over commercially available gemcitabine may be obtained by increasing the amount of gemcitabine administered while decreasing the frequency of dosing. In other words, lower treatment frequency resulted in equivalent efficacy to current gemcitabine dosing regimens.

CLAIMS

1. A cytotoxic particle including:

- a core;

- a cytotoxic compound contained in, or entrapped in or on said core;

5 - a plurality of variable domains arranged on the core for binding to P2X₇R on a cancer cell thereby enabling the particle to bind to a cancer cell having P2X₇R expressed thereon when the particle is contacted with the cancer cell.

2. The particle of claim 1 wherein the core is a liposome.

3. The particle of claim 1 or 2 wherein the cytotoxic compound is
10 gemcitabine.

4. The particle of claim 3 wherein the liposome includes hydrocarbon chains forming a lipid layer of the liposome and wherein the primary amine of gemcitabine is bonded to a hydrocarbon chain of the lipid layer via a carbamate group.

5. The particle of claims 3 or 4 wherein the liposome includes maleimide
15 groups arranged thereon enabling conjugation of an antibody to the liposome.

6. The particle of any one of claims 1 to 5, wherein the variable domain binds to a peptide consisting of the sequence GHNYTTNILPGLNITC (**SEQ ID NO: 2**).

7. The particle of any one of claims 1 to 5, wherein the variable domain binds to a peptide consisting of the sequence KYYKENNVEKRTLK (**SEQ ID NO: 3**).

20 8. The particle of any one of claims 1 to 7, wherein the variable domains arranged on the core for binding to P2X₇ receptors on a cancer cell may be provided in the form of a whole antibody, or a fragment of an antibody that includes a variable domain.

9. The particle of any one of claims 1 to 8, wherein the variable domains are
25 for binding to cancer associated -P2X₇ receptors.

10. The particle of claim 9, wherein the variable domains are for binding to non-functional P2X₇ receptors.

11. The particle of claim 8, wherein fragment of an antibody that includes a variable domain includes single chain antibodies, single chain Fv fragments, and
5 F(ab')₂, Fab, Fd and Fv fragments.

12. The particle of any one of the preceding claims wherein the variable domain is defined by Formula 1:

CDR1-CDR2-CDR3

wherein CDR1 is RNHDMG (SEQ ID NO: 4)

10 wherein CDR2 is AISGSGGSTYYANSVKG (SEQ ID NO: 5)

wherein CDR3 is EPKPMDTTEFDY (SEQ ID NO: 6)

13. The particle of any one of the preceding claims wherein the variable domain comprises the amino acid sequence as shown in SEQ ID NO: 7.

14. The particle of any one of the preceding claims wherein the variable
15 domain consisting of the amino acid sequence as shown in SEQ ID NO: 7.

15. A pharmaceutical composition including a plurality of cytotoxic particles of any one of the preceding claims and a pharmaceutically effective diluent, excipient or carrier.

16. A method of treating an individual having cancer including administering a
20 particle or composition of any one of claims 1 to 14 to the individual, thereby treating the individual for cancer.

17. The method of claim 16, wherein the cancer is a solid tumour.

18. The method of claim 17, wherein the cancer is breast cancer.

19. A particle or composition of any one of claims 1 to 15 for use in the
25 treatment of an individual having cancer.

20. Use of a particle or composition of any one of claims 1 to 15 in the manufacture of a medicament for the treatment of cancer.

21. A method for killing a cancer cell including contacting a cancer cell with a particle or composition of any one of claims 1 to 15.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 9 continued...




Figure 10

Efficacy of 4T1 mouse breast cancer tumour suppression of Gem prodrug NP and antibody targeted NPs against PBS and Gemcitabine




Figure 10 continued...




Figure 11





Figure 11 continued...



INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2017/050885

A. CLASSIFICATION OF SUBJECT MATTER

A61K 9/127 (2006.01) A61K 47/69 (2017.01) A61K 39/395 (2006.01) A61K 31/7068 (2006.01) A61P 35/00 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PATENW, MEDLINE, CAPLUS, BIOSIS, EMBASE and the following keywords and CPC/IPC marks: P2X7, P2X7R, Purinergic receptor 7, P2Z receptor, purinoreceptor P2Z, antibody, immunoglobulin, single chain Fv, nanobody, immunoliposome, liposome, particle, microemulsion, macroemulsion, vesicle, micelle, nanosphere, microsphere, nanocapsule, microcapsule, nanobead, microbead, cytotoxic, chemotherapy, gemcitabine, carbamate, maleimide, E200, E300, GHNYTTNLPGLNITC, KYYKENNVEKRTLK and related terms. CPC/IPC marks: A61K 47/6913, A61K 47/69.

GenomeQuest protein databases: SEQ ID NOs: 4, 5 and 6.

Applicant/Inventor name search using the databases Patentscope, PubMed and Auspat and IP Australia internal databases.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	



Further documents are listed in the continuation of Box C



See patent family annex

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 9 November 2017		Date of mailing of the international search report 09 November 2017	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au		Authorised officer Shawn Lyons AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. +61262832081	

INTERNATIONAL SEARCH REPORT C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		International application No. PCT/AU2017/050885
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2011/020155 A1 (BIOSCEPTRE INTERNATIONAL LIMITED) 24 February 2011 See the abstract; page 9, lines 7-9; page 59, lines 11-19; page 49, lines 6-17; SEQ ID NO: 174 (PEP2-2); the section entitled "Results" on pages 76-78; page 70, line 29 - page 72, line 30	1-21
X	WO 2013/003895 A1 (BIOSCEPTRE INTERNATIONAL LIMITED) 10 January 2013 See page 20, lines 20-22; page 24, lines 12-13; page 29, line 7 - page 31, line 11; page 20, lines 14-19; page 9, lines 10-15	1-21
X	WO 2012/031333 A1 (BIOSCEPTRE INTERNATIONAL LIMITED) 15 March 2012 See the paragraph bridging pages 20-21; the first complete paragraph of page 21; page 10, lines 4-10; the paragraph bridging pages 27-28; page 25, lines 18-19	1-21
A	CHENG W.W. and ALLEN T.M., "The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment", Expert Opinion on Drug Delivery, 2010, Vol. 7, No. 4, pages 461-478 See the abstract; Figure 1	1-21
A	KONTERMANN R., "Immunoliposomes for cancer therapy", Current Opinion in Molecular Therapeutics, 2006, Vol. 8, No. 1, pages 39-45 See the abstract; Figure 1 and Table 1; the section entitled "ScFv fragments"; the section entitled "Single-domain antibodies and novel binding proteins"	1-21
A	STEELAND S. et al., "Nanobodies as therapeutics: big opportunities for small antibodies", Drug Discovery Today, July 2016, Vol. 21, No. 7, pages 1076-1113 See Figure 1(b); the second paragraph of the section entitled "Nbs incorporated into drug delivery systems" on page 1090	1-21
Form PCT/ISA/210 (fifth sheet) (July 2009)		

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/AU2017/050885	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2011/020155 A1	24 February 2011	WO 2011020155 A1	24 Feb 2011
		EP 2467404 A1	27 Jun 2012
		EP 2467404 B1	30 Sep 2015
		EP 2966090 A1	13 Jan 2016
		HK 1168365 A1	29 Jul 2016
		JP 2013502204 A	24 Jan 2013
		JP 5936067 B2	15 Jun 2016
		JP 2016136949 A	04 Aug 2016
		US 2012282278 A1	08 Nov 2012
		US 9127059 B2	08 Sep 2015
		US 2015266969 A1	24 Sep 2015
		US 9688771 B2	27 Jun 2017
		WO 2013/003895 A1	10 January 2013
AU 2012278921 A1	16 Jan 2014		
AU 2012278921 B2	10 Nov 2016		
BR 112013033974 A2	14 Feb 2017		
CA 2840251 A1	10 Jan 2013		
CN 103702683 A	02 Apr 2014		
CN 103702683 B	04 Jul 2017		
EP 2726095 A1	07 May 2014		
JP 2014520759 A	25 Aug 2014		
MX 2014000199 A	11 Jun 2014		
US 2015004179 A1	01 Jan 2015		
US 9566318 B2	14 Feb 2017		
US 2017157229 A1	08 Jun 2017		
WO 2012/031333 A1	15 March 2012	WO 2012031333 A1	15 Mar 2012
		AU 2011301153 A1	28 Mar 2013
		AU 2011301153 B2	27 Nov 2014
		CN 103298487 A	11 Sep 2013
		CN 106310245 A	11 Jan 2017
		EP 2613808 A1	17 Jul 2013
		US 2013266592 A1	10 Oct 2013
		US 9562094 B2	07 Feb 2017
		US 2017232085 A1	17 Aug 2017
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT Information on patent family members		International application No. PCT/AU2017/050885	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
End of Annex			
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. Form PCT/ISA/210 (Family Annex)(July 2009)			